Bayer clinches $2.9B Algeta deal; Hypermarcas profits dive 56% in Q4 despite higher sales;

@FiercePharma: With Teva's Symbicort copy nearing EU launch, AstraZeneca preps for battle. Story | Follow @FiercePharma

@TracyStaton: Top story at FiercePharma over weekend: FDA moves toward major overhaul in the way it approves OTC meds. More | Follow @TracyStaton

@EricPFierce: GSK could get some financial breathing room with an EU nod for Anoro. Report | Follow @EricPFierce

@CarlyHFierce: Vertex eyes another $45 million in sales as FDA swells Kalydeco's patient pool. News | Follow @CarlyHFierce

> Bayer has snagged a $2.9 billion deal for Norway's Algeta. Report

> Profits for Brazil's Hypermarcas sank 56% in Q4, with higher sales undercut by the financial cost of a weaker currency and repurchases of bonds. More

> Eli Lilly ($LLY) will pick up Germany's Lohmann Animal Health for an undisclosed sum. Report

> Private equity firm TPG plans to take healthcare company Chindex International ($CHDX) private in a $369 million deal, which will make China's Fosun Pharma its largest shareholder. News

> Roche ($RHHBY) has tapped real estate firm Jones Lang LaSalle to sell its campus, which measures approximately 120 acres and encompasses parts of New Jersey towns Nutley and Clifton. Report

> KV Pharmaceuticals has tabbed Gregg Raybuck as president of its new maternal health division, part of a larger restructuring that also created a new women's healthcare division. News

> A Maryland federal judge Friday shut down Par Pharmaceutical's bid to keep its patent for Megace ES, a drug that fights anorexia and extreme weight loss in AIDS patients. More (sub. req.)

Medical Device News

@FierceMedDev: German study backs a Japanese firm's dissolving stent over the bare metal variety. Story | Follow @FierceMedDev

@MichaelGFierce: Capsule Tech launches a medical device integration system with a few big partners. More | Follow @MichaelGFierce

@EmilyWFierce: 3-D printing technology could be used to construct human organs, say scientists. Article | Follow @EmilyWFierce

@GalenMoore: Startup Constant Therapy raises seed funds for its iPad-based brain injury treatment. More | Follow @GalenMoore

> Endo is stocking up at least $520M to cover vaginal mesh lawsuit legal costs. Story

> Boston Scientific partners up to push Parkinson's tech in Europe. Article

Biotech News

@FierceBiotech: Assessing the crowd effect on biopharma's risky R&D strategy. More | Follow @FierceBiotech

@JohnCFierce: Bristol-Myers picks up another "breakthrough" trophy in hep C cocktail showdown. News | Follow @JohnCFierce

@DamianFierce: As Big Pharma sells/spins out its animal health ops, Lilly buys one. Release | Follow @DamianFierce

@EmilyMFierce: Gene therapy regenerates damaged tissue in pigs after heart attack. Story | Follow @EmilyMFierce

> DNAtrix bags $10.8M to advance its cancer-killing virus. Story

> Busy Servier grabs an option on Celladon's early-stage diabetes work. News

CRO News

> Medpace changes hands for $915M as private equity smiles on CROs. News

> After soaring 20% in 2013, Icon eyes a bigger share of the CRO market. Article

> Quintiles lends its sequencing skills to massive cardiovascular study. Story

> Parexel expands its regulatory reach with latest move. News

> PPD partners up to give Germany a starring role in clinical trials. Story

> Charles River amps up its biologics testing. Item

Biotech IT News

> Buzz: BGI is preparing for a $400M Hong Kong IPO in Q4. Report

> U.K. delays patient database project following public backlash. News

> Roche mulls sharing Avastin trial data to clear up possible statistical quirk. Story

> U.S. team taps supercomputer to accelerate genome data analysis. Article

> Merge prepares to defend itself against fake contract lawsuits. News

> Pfizer CEO begins contributing to LinkedIn's publishing platform. Brief

And Finally... Will e-cigarettes help eradicate conventional smoking or serve as a gateway to tobacco use? Story (sub. req.)

Suggested Articles

The CD19 antibody, used in tandem with Celgene's Revlimid, represents the first FDA approval in second-line diffuse large B-cell lymphoma.

Sanofi has faced a probe into birth defects tied to seizure med Depakine for years. Now, the investigation is moving forward on manslaughter charges.

Pfizer launched a multichannel awareness campaign centered on a first-ever radio station dedicated solely to metastatic breast cancer.